<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00846859</url>
  </required_header>
  <id_info>
    <org_study_id>GOTABU-BO2</org_study_id>
    <nct_id>NCT00846859</nct_id>
  </id_info>
  <brief_title>Does Varenicline Influence Alcohol Consumption in Alcohol Dependent Individuals?</brief_title>
  <official_title>Does Varenicline Influence Alcohol Consumption in Alcohol Dependent Individuals?</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sahlgrenska University Hospital, Sweden</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Karolinska University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Malmö University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Sahlgrenska University Hospital, Sweden</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the present clinical trial is to investigate whether 14 weeks of treatment with a
      prescription medication for smoking cessation (European trade name: Champix(R); US trade
      name: Chantix(R)), can reduce alcohol consumption in alcohol dependent individuals.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2009</start_date>
  <completion_date type="Actual">January 2011</completion_date>
  <primary_completion_date type="Actual">August 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Alcohol consumption as measured by diary and questionnaires: the number of heavy drinking days (as percentage) defined as ≥5 standard drinks per day for men and ≥4 standard drinks per day for women</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Alcohol consumption as measured by diary and questionnaires: total amount (grams) of consumed alcohol compared to baseline.</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage (and number) of abstaining days compared to baseline.</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Drinks per drinking day compared to baseline.</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Alcohol consumption as measured by alcohol markers in blood compared to baseline.</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nicotine use in alcohol dependent subjects as measured by diary and questionnaires compared to baseline.</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compliance as measured by diary and returned medication packages.</measure>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">162</enrollment>
  <condition>Alcohol Dependence</condition>
  <arm_group>
    <arm_group_label>varenicline</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>varenicline (Champix/Chantix)</intervention_name>
    <description>14 weeks of per oral tablet treatment in an escalating dosing regimen (0.5 mg - 1.0 mg/day; 1 - 2 tablets/day).</description>
    <arm_group_label>varenicline</arm_group_label>
    <other_name>Champix(R)/Chantix(R)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo for varenicline</intervention_name>
    <description>14 weeks of per oral tablet treatment in an escalating dosing regimen (1 - 2 tablets/day)</description>
    <arm_group_label>placebo</arm_group_label>
    <other_name>placebo for Champix(R) / Chantix(R)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age: 30-70 years at screening

          2. Alcohol dependence according to DSM-IV (meeting ≥3 out of 7 criteria)

          3. ≥ 20 heavy drinking days (men: ≥ 5 drinks/day, women: ≥4 drinks/day, where 1 std.
             drink is defined as 12 g ethanol) during the last 60 days

          4. Participants must have signed the informed consent

        Exclusion Criteria:

          1. Subject to treatment of alcohol withdrawal within 30 days of study initiation

          2. Subject to treatment that may affect alcohol consumption including acamprosate,
             naltrexone, disulfiram, ondansetron, topiramate, SSRIs, varenicline, mirtazapine,
             rimonabant, methylphenidate or atomoxetine within 3 months of study initiation

          3. Subject to treatment of depression within 3 months of study initiation

          4. The continuous use of drugs such as codeine, hydroxyzine, alimemazine, benzodiazepines
             or sedatives (the sporadic use of these compounds is accepted)

          5. Any concurrent medication that may affect the results of the trial or is considered to
             compromise the safety of the participants in the trial

          6. History of Delirium Tremens the last 5 years or any history of abstinence-induced
             seizures

          7. Laboratory hepatic values of more than 3 times the upper limit of the normal range or
             other clinically significant abnormalities in the screening laboratory values.

          8. Participants who are pregnant or nursing infant(s), and women of childbearing
             potential not using a contraceptive method judged by the investigator to be effective.

          9. Any ongoing serious psychiatric or somatic disorder

         10. Any psychiatric Axel I diagnoses (except for nicotine or alcohol dependence)

         11. The concurrent use of illicit drugs based on urine-toxicity test

         12. The need for detoxification

         13. Diabetes Mellitus Type 1

         14. Suicidal risk

         15. Homelessness

         16. Additional factors that implies to the investigator/physician that the participant
             will not be completing the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Elin Löf, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Addiction Biology Unit, University of Gothenburg and Beroendekliniken, Sahlgrenska University Hospital, Sweden</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Bo Söderpalm, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Addiction Biology Unit, University of Gothenburg and Beroendekliniken, Sahlgrenska University Hospital, Sweden</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Addiction Biology Unit, Beroendekliniken, University of Gothenburg and Sahlgrenska University Hospital</name>
      <address>
        <city>Gothenburg</city>
        <zip>413 45</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beroendecentrum, Malmö University Hospital (UMAS), Sweden</name>
      <address>
        <city>Malmö</city>
        <zip>205 02</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Clinical Neuroscience Section of Dependence Research Magnus Huss Clinic: M4:02 Karolinska University Hospital</name>
      <address>
        <city>Stockholm</city>
        <zip>171 76</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <reference>
    <citation>Ericson M, Löf E, Stomberg R, Söderpalm B. The smoking cessation medication varenicline attenuates alcohol and nicotine interactions in the rat mesolimbic dopamine system. J Pharmacol Exp Ther. 2009 Apr;329(1):225-30. doi: 10.1124/jpet.108.147058. Epub 2009 Jan 6.</citation>
    <PMID>19126781</PMID>
  </reference>
  <reference>
    <citation>Löf E, Olausson P, deBejczy A, Stomberg R, McIntosh JM, Taylor JR, Söderpalm B. Nicotinic acetylcholine receptors in the ventral tegmental area mediate the dopamine activating and reinforcing properties of ethanol cues. Psychopharmacology (Berl). 2007 Dec;195(3):333-43. Epub 2007 Aug 17.</citation>
    <PMID>17703283</PMID>
  </reference>
  <reference>
    <citation>Löf E, Chau PP, Stomberg R, Söderpalm B. Ethanol-induced dopamine elevation in the rat--modulatory effects by subchronic treatment with nicotinic drugs. Eur J Pharmacol. 2007 Jan 26;555(2-3):139-47. Epub 2006 Oct 28.</citation>
    <PMID>17141214</PMID>
  </reference>
  <reference>
    <citation>Söderpalm B, Ericson M, Olausson P, Blomqvist O, Engel JA. Nicotinic mechanisms involved in the dopamine activating and reinforcing properties of ethanol. Behav Brain Res. 2000 Aug;113(1-2):85-96. Review.</citation>
    <PMID>10942035</PMID>
  </reference>
  <reference>
    <citation>Ericson M, Blomqvist O, Engel JA, Söderpalm B. Voluntary ethanol intake in the rat and the associated accumbal dopamine overflow are blocked by ventral tegmental mecamylamine. Eur J Pharmacol. 1998 Oct 9;358(3):189-96.</citation>
    <PMID>9822883</PMID>
  </reference>
  <reference>
    <citation>Blomqvist O, Ericson M, Engel JA, Söderpalm B. Accumbal dopamine overflow after ethanol: localization of the antagonizing effect of mecamylamine. Eur J Pharmacol. 1997 Sep 10;334(2-3):149-56.</citation>
    <PMID>9369343</PMID>
  </reference>
  <reference>
    <citation>Blomqvist O, Söderpalm B, Engel JA. Ethanol-induced locomotor activity: involvement of central nicotinic acetylcholine receptors? Brain Res Bull. 1992 Aug;29(2):173-8.</citation>
    <PMID>1525672</PMID>
  </reference>
  <reference>
    <citation>Blomqvist O, Engel JA, Nissbrandt H, Söderpalm B. The mesolimbic dopamine-activating properties of ethanol are antagonized by mecamylamine. Eur J Pharmacol. 1993 Nov 9;249(2):207-13.</citation>
    <PMID>8287902</PMID>
  </reference>
  <reference>
    <citation>Steensland P, Simms JA, Holgate J, Richards JK, Bartlett SE. Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, selectively decreases ethanol consumption and seeking. Proc Natl Acad Sci U S A. 2007 Jul 24;104(30):12518-23. Epub 2007 Jul 11.</citation>
    <PMID>17626178</PMID>
  </reference>
  <reference>
    <citation>Blomqvist O, Hernandez-Avila CA, Van Kirk J, Rose JE, Kranzler HR. Mecamylamine modifies the pharmacokinetics and reinforcing effects of alcohol. Alcohol Clin Exp Res. 2002 Mar;26(3):326-31.</citation>
    <PMID>11923584</PMID>
  </reference>
  <reference>
    <citation>Young EM, Mahler S, Chi H, de Wit H. Mecamylamine and ethanol preference in healthy volunteers. Alcohol Clin Exp Res. 2005 Jan;29(1):58-65.</citation>
    <PMID>15654292</PMID>
  </reference>
  <reference>
    <citation>Chi H, de Wit H. Mecamylamine attenuates the subjective stimulant-like effects of alcohol in social drinkers. Alcohol Clin Exp Res. 2003 May;27(5):780-6.</citation>
    <PMID>12766622</PMID>
  </reference>
  <reference>
    <citation>Rollema H, Chambers LK, Coe JW, Glowa J, Hurst RS, Lebel LA, Lu Y, Mansbach RS, Mather RJ, Rovetti CC, Sands SB, Schaeffer E, Schulz DW, Tingley FD 3rd, Williams KE. Pharmacological profile of the alpha4beta2 nicotinic acetylcholine receptor partial agonist varenicline, an effective smoking cessation aid. Neuropharmacology. 2007 Mar;52(3):985-94. Epub 2006 Dec 8.</citation>
    <PMID>17157884</PMID>
  </reference>
  <reference>
    <citation>Tonstad S. Varenicline for smoking cessation. Expert Rev Neurother. 2007 Feb;7(2):121-7. Review.</citation>
    <PMID>17286546</PMID>
  </reference>
  <reference>
    <citation>Jorenby DE, Hays JT, Rigotti NA, Azoulay S, Watsky EJ, Williams KE, Billing CB, Gong J, Reeves KR; Varenicline Phase 3 Study Group. Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial. JAMA. 2006 Jul 5;296(1):56-63. Erratum in: JAMA. 2006 Sep 20;296(11):1355.</citation>
    <PMID>16820547</PMID>
  </reference>
  <reference>
    <citation>Gonzales D, Rennard SI, Jorenby DE, Reeves KR. Comment: Oral varenicline for smoking cessation. Ann Pharmacother. 2007 Apr;41(4):720-1. Epub 2007 Mar 20.</citation>
    <PMID>17374627</PMID>
  </reference>
  <reference>
    <citation>Daeppen JB, Smith TL, Danko GP, Gordon L, Landi NA, Nurnberger JI Jr, Bucholz KK, Raimo E, Schuckit MA. Clinical correlates of cigarette smoking and nicotine dependence in alcohol-dependent men and women. The Collaborative Study Group on the Genetics of Alcoholism. Alcohol Alcohol. 2000 Mar-Apr;35(2):171-5.</citation>
    <PMID>10787393</PMID>
  </reference>
  <reference>
    <citation>Larsson A, Jerlhag E, Svensson L, Söderpalm B, Engel JA. Is an alpha-conotoxin MII-sensitive mechanism involved in the neurochemical, stimulatory, and rewarding effects of ethanol? Alcohol. 2004 Oct-Nov;34(2-3):239-50.</citation>
    <PMID>15902919</PMID>
  </reference>
  <reference>
    <citation>Larsson A, Svensson L, Söderpalm B, Engel JA. Role of different nicotinic acetylcholine receptors in mediating behavioral and neurochemical effects of ethanol in mice. Alcohol. 2002 Nov;28(3):157-67.</citation>
    <PMID>12551757</PMID>
  </reference>
  <reference>
    <citation>Larsson A, Edström L, Svensson L, Söderpalm B, Engel JA. Voluntary ethanol intake increases extracellular acetylcholine levels in the ventral tegmental area in the rat. Alcohol Alcohol. 2005 Sep-Oct;40(5):349-58. Epub 2005 Jul 25.</citation>
    <PMID>16043436</PMID>
  </reference>
  <reference>
    <citation>Bohn MJ, Babor TF, Kranzler HR. The Alcohol Use Disorders Identification Test (AUDIT): validation of a screening instrument for use in medical settings. J Stud Alcohol. 1995 Jul;56(4):423-32.</citation>
    <PMID>7674678</PMID>
  </reference>
  <reference>
    <citation>Anton RF, Moak DH, Latham P. The Obsessive Compulsive Drinking Scale: a self-rated instrument for the quantification of thoughts about alcohol and drinking behavior. Alcohol Clin Exp Res. 1995 Feb;19(1):92-9.</citation>
    <PMID>7771669</PMID>
  </reference>
  <reference>
    <citation>Wilson CB, Gutin P, Boldrey EB, Drafts D, Levin VA, Enot KJ. Single-agent chemotherapy of brain tumors. A five-year review. Arch Neurol. 1976 Nov;33(11):739-44.</citation>
    <PMID>185991</PMID>
  </reference>
  <verification_date>July 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 17, 2009</study_first_submitted>
  <study_first_submitted_qc>February 17, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 19, 2009</study_first_posted>
  <last_update_submitted>July 20, 2011</last_update_submitted>
  <last_update_submitted_qc>July 20, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 21, 2011</last_update_posted>
  <responsible_party>
    <name_title>Bo Söderpalm/ MD, PhD, sponsor</name_title>
    <organization>Addiction Biology Unit, Sahlgrenska University Hospital, Sweden</organization>
  </responsible_party>
  <keyword>alcohol dependence</keyword>
  <keyword>nicotine dependence</keyword>
  <keyword>alcohol abuse</keyword>
  <keyword>varenicline</keyword>
  <keyword>Champix</keyword>
  <keyword>Chantix</keyword>
  <keyword>smoking</keyword>
  <keyword>drinking</keyword>
  <keyword>snuffing</keyword>
  <keyword>diary</keyword>
  <keyword>phosphatidyl ethanol</keyword>
  <keyword>PEth</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alcoholism</mesh_term>
    <mesh_term>Alcohol Drinking</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ethanol</mesh_term>
    <mesh_term>Varenicline</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

